Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Mereo BioPharma (MREO) Invested Capital (2020 - 2025)

Historic Invested Capital for Mereo BioPharma (MREO) over the last 6 years, with Q3 2025 value amounting to $46.6 million.

  • Mereo BioPharma's Invested Capital fell 3575.88% to $46.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.6 million, marking a year-over-year decrease of 3575.88%. This contributed to the annual value of $61.0 million for FY2024, which is 2064.23% up from last year.
  • As of Q3 2025, Mereo BioPharma's Invested Capital stood at $46.6 million, which was down 3575.88% from $54.2 million recorded in Q2 2025.
  • Mereo BioPharma's Invested Capital's 5-year high stood at $138.0 million during Q4 2021, with a 5-year trough of $42.8 million in Q1 2024.
  • In the last 5 years, Mereo BioPharma's Invested Capital had a median value of $60.1 million in 2025 and averaged $67.6 million.
  • Per our database at Business Quant, Mereo BioPharma's Invested Capital skyrocketed by 54752.16% in 2021 and then crashed by 6240.47% in 2022.
  • Mereo BioPharma's Invested Capital (Quarter) stood at $138.0 million in 2021, then tumbled by 62.4% to $51.9 million in 2022, then decreased by 2.6% to $50.5 million in 2023, then increased by 20.64% to $61.0 million in 2024, then fell by 23.57% to $46.6 million in 2025.
  • Its last three reported values are $46.6 million in Q3 2025, $54.2 million for Q2 2025, and $60.1 million during Q1 2025.